Skip to content
OpenCapital
Get started

Agios Pharmaceuticals AGIO Available For Sale Securities Debt Securities Current

Available For Sale Securities Debt Securities Current at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$912M+0.6%
Pfizer logo
PfizerPFE
——
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
——
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
——
BridgeBio Pharma logo
BridgeBio PharmaBBIO
——

Other financials

Income statement

See full
Revenue$20.7M+138%
Gross profit$19.4M+154%
Operating income-$110.0M-3.2%
Net income-$99.1M-11.0%
EPS (diluted)-$1.69-9.0%

Balance sheet

See full
Cash & equivalents$113.6M+43.9%
Total debt$35.7M-32.5%
Total equity$1.1B-24.4%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow-$118.9M-6.7%
CapEx$769.0K+0.4%
Free cash flow-$119.7M-6.6%

Valuation

See full
Market cap$2.16B+18.1%
Enterprise value$2.08B+15.2%
P/S32.7×-16.7×

Profitability

See full
Gross margin90%+2.5pp
Operating margin-720%-204pp
Net margin-639.8%—
FCF margin-582.5%-185pp

Returns & leverage

See full
Return on equity-32.8%—
Debt / equity0×0.0×
Current ratio14.2×-4.3×

Where this comes from

Reported directly by Agios Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Agios Pharmaceuticals's available for sale securities debt securities current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Agios Pharmaceuticals's available for sale securities debt securities current?
Agios Pharmaceuticals (AGIO) reported available for sale securities debt securities current of $623.44M in Q1 2026.
How has Agios Pharmaceuticals's available for sale securities debt securities current changed year-over-year?
Agios Pharmaceuticals's available for sale securities debt securities current decreased by 23.4% year-over-year, from $814.41M to $623.44M.
What is the long-term trend for Agios Pharmaceuticals's available for sale securities debt securities current?
Over 5 years (2020 to 2025), Agios Pharmaceuticals's available for sale securities debt securities current has grown at a 11.4% compound annual growth rate (CAGR), from $445.49M to $765.3M.